Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 620.91 Million CNY | -13.58% |
| 2022 | 650.14 Million CNY | -25.75% |
| 2021 | 875.62 Million CNY | -18.79% |
| 2020 | 1.07 Billion CNY | -19.18% |
| 2019 | 1.33 Billion CNY | 40.45% |
| 2018 | 949.85 Million CNY | 51.69% |
| 2017 | 626.19 Million CNY | 51.22% |
| 2016 | 414.09 Million CNY | 15.87% |
| 2015 | 357.38 Million CNY | 22.67% |
| 2014 | 291.33 Million CNY | 1.01% |
| 2013 | 288.43 Million CNY | 14.34% |
| 2012 | 252.25 Million CNY | 26.21% |
| 2011 | 199.87 Million CNY | 44.81% |
| 2010 | 138.02 Million CNY | 14.04% |
| 2009 | 121.03 Million CNY | 26.4% |
| 2008 | 95.75 Million CNY | 60.07% |
| 2007 | 59.82 Million CNY | 49.69% |
| 2006 | 39.96 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 121.35 Million CNY | 3.37% |
| 2024 Q3 | 135.47 Million CNY | 11.64% |
| 2024 Q1 | 117.39 Million CNY | -26.37% |
| 2023 Q3 | 129.04 Million CNY | -17.89% |
| 2023 Q4 | 159.44 Million CNY | 23.56% |
| 2023 Q2 | 157.16 Million CNY | -2.03% |
| 2023 FY | 561.85 Million CNY | -13.58% |
| 2023 Q1 | 160.42 Million CNY | 1.42% |
| 2022 Q1 | 145.71 Million CNY | -40.88% |
| 2022 Q2 | 145.39 Million CNY | -0.22% |
| 2022 Q3 | 200.86 Million CNY | 38.15% |
| 2022 Q4 | 158.17 Million CNY | -21.25% |
| 2022 FY | 650.14 Million CNY | -25.75% |
| 2021 Q4 | 246.48 Million CNY | 29.07% |
| 2021 FY | 875.62 Million CNY | -18.79% |
| 2021 Q2 | 177.64 Million CNY | -31.81% |
| 2021 Q3 | 190.97 Million CNY | 7.5% |
| 2021 Q1 | 260.52 Million CNY | -21.1% |
| 2020 Q2 | 250.12 Million CNY | 40.69% |
| 2020 Q4 | 330.21 Million CNY | 3.16% |
| 2020 Q1 | 177.77 Million CNY | -58.85% |
| 2020 FY | 1.07 Billion CNY | -19.18% |
| 2020 Q3 | 320.09 Million CNY | 27.97% |
| 2019 Q3 | 346.43 Million CNY | -1.14% |
| 2019 FY | 1.33 Billion CNY | 40.45% |
| 2019 Q1 | 205.16 Million CNY | -34.01% |
| 2019 Q2 | 350.41 Million CNY | 70.79% |
| 2019 Q4 | 432.05 Million CNY | 24.71% |
| 2018 FY | 949.85 Million CNY | 51.69% |
| 2018 Q4 | 310.91 Million CNY | 28.21% |
| 2018 Q3 | 242.5 Million CNY | 15.51% |
| 2018 Q2 | 209.94 Million CNY | 12.57% |
| 2018 Q1 | 186.49 Million CNY | -22.29% |
| 2017 Q1 | 96.93 Million CNY | -31.78% |
| 2017 Q3 | 174.01 Million CNY | 50.99% |
| 2017 FY | 626.19 Million CNY | 51.22% |
| 2017 Q4 | 239.99 Million CNY | 37.91% |
| 2017 Q2 | 115.24 Million CNY | 18.9% |
| 2016 FY | 414.09 Million CNY | 15.87% |
| 2016 Q1 | 89.31 Million CNY | -27.13% |
| 2016 Q2 | 80.64 Million CNY | -9.7% |
| 2016 Q3 | 102.04 Million CNY | 26.54% |
| 2016 Q4 | 142.08 Million CNY | 39.23% |
| 2015 Q2 | 79.53 Million CNY | -1.38% |
| 2015 Q1 | 80.65 Million CNY | -20.75% |
| 2015 Q3 | 74.62 Million CNY | -6.18% |
| 2015 FY | 357.38 Million CNY | 22.67% |
| 2015 Q4 | 122.56 Million CNY | 64.23% |
| 2014 Q3 | 83.02 Million CNY | 44.2% |
| 2014 Q4 | 101.77 Million CNY | 22.59% |
| 2014 Q2 | 57.57 Million CNY | 17.58% |
| 2014 Q1 | 48.96 Million CNY | -42.53% |
| 2014 FY | 291.33 Million CNY | 1.01% |
| 2013 Q4 | 85.2 Million CNY | 28.54% |
| 2013 Q3 | 66.28 Million CNY | -8.32% |
| 2013 Q2 | 72.3 Million CNY | 11.87% |
| 2013 Q1 | 64.63 Million CNY | 3.38% |
| 2013 FY | 288.43 Million CNY | 14.34% |
| 2012 FY | 252.25 Million CNY | 26.21% |
| 2012 Q3 | 62.82 Million CNY | -0.42% |
| 2012 Q2 | 63.08 Million CNY | -1.16% |
| 2012 Q4 | 62.51 Million CNY | -0.49% |
| 2012 Q1 | 63.82 Million CNY | 47.39% |
| 2011 Q2 | 54.01 Million CNY | 3.4% |
| 2011 FY | 199.87 Million CNY | 44.81% |
| 2011 Q1 | 52.24 Million CNY | 41.08% |
| 2011 Q4 | 43.3 Million CNY | -13.92% |
| 2011 Q3 | 50.31 Million CNY | -6.86% |
| 2010 Q1 | 33.42 Million CNY | 0.47% |
| 2010 Q3 | 32.29 Million CNY | -8.49% |
| 2010 Q4 | 37.02 Million CNY | 14.67% |
| 2010 FY | 138.02 Million CNY | 14.04% |
| 2010 Q2 | 35.28 Million CNY | 5.58% |
| 2009 FY | 121.03 Million CNY | 26.4% |
| 2009 Q4 | 33.26 Million CNY | 0.44% |
| 2009 Q3 | 33.12 Million CNY | 19.56% |
| 2009 Q2 | 27.7 Million CNY | 2.82% |
| 2009 Q1 | 26.94 Million CNY | -11.03% |
| 2008 FY | 95.75 Million CNY | 60.07% |
| 2008 Q4 | 30.28 Million CNY | 29.11% |
| 2008 Q3 | 23.45 Million CNY | 0.0% |
| 2007 FY | 59.82 Million CNY | 49.69% |
| 2006 FY | 39.96 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 2.18 Billion CNY | 71.647% |
| Zhejiang Zhenyuan Share Co., Ltd. | 762.64 Million CNY | 18.584% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 458.96 Million CNY | -35.284% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 187.93 Million CNY | -230.389% |
| Yifan Pharmaceutical Co., Ltd. | 1.83 Billion CNY | 66.087% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 347.72 Million CNY | -78.567% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 10.7 Billion CNY | 94.198% |
| Boai NKY Medical Holdings Ltd. | 894.38 Million CNY | 30.577% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 808 Million CNY | 23.154% |